NZ to fund use of GlaxoSmithKline's HIV drugs Kivexa and Tivicay

11 October 2016

New Zealand’s Pharmaceutical Management Agency PHARMAC has reached agreement with the local subsidiary of UK pharma major GlaxoSmithKline (LSE: GSK) for the funding of the HIV treatments, dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa).

Following a consultation letter dated September 8, no changes were made to the proposal following consultation. In summary, the effect of the decision is that from 1 November 2016:

Tivicay will be will be fully funded in District Health Board (DHB) hospitals and the community, subject to certain clinical criteria being met; and
There will be a decrease in the price and subsidy of Kivexa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK